GeneQuine develops gene therapy-based drugs for the treatment of osteoarthritis. The goal is the development of gene therapy drugs for osteoarthritis in humans. However, veterinary drug development is an attractive area as well because regulatory hurdles, development risk and development costs for veterinary drugs are markedly lower and market approval can be gained faster compared with human medicines. Thus, GeneQuine is also developing drug candidates for horses and dogs.
Management
Kilian Guse, PhD
CEO, Co-Founder
Dr. Guse has more than 10 years experience in the field of gene therapy and is author of more than 30 scientific publications in international, peer-reviewed journals and book chapters on this topic.
Stanislav Plutizki, PhD
COO, Co-Founder
Prior to co-founding and working for GeneQuine, Dr. Plutizki was international medical manager at the regulatory and global medical marketing department at Berlin Chemie AG (Menarini Group), Berlin, Germany, where he was responsible for medical and scientific management of a large product portfolio.
Advisory Board
Yves Henrotin, Prof.
Clinical and Scientific Advisor
Professor of Pathology, Physical Therapy and Rehabilitation and Director of the Bone and Cartilage Research Unit at the University of Liège, Belgium; President of Osteoarthritis Foundation.
Peter Johann, PhD
Advisory Board
Dr. Peter Johann is CEO of Lumendi Ltd. and a managing general partner of NGN Capital.
Collaborations
Baylor College of Medicine
Baylor College of Medicine (BCM), located in Houston, Texas, USA is one of the leading medical schools and biomedical research institutes in the country.
Cornell University
Cornell University is an Ivy League research university located in Ithaca, New York, USA.
Flexion Therapeutics, Inc.
Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis.